



# **The Human Tumor Atlas Network:** *Charting Tumor Transitions Across Space and Time*

**Session Title: Resources from the NCI-Sponsored Human Tumor Atlas Network**

Sharmistha Ghosh-Janjigian, PhD  
Program Director  
Division of Cancer Biology  
National Cancer Institute (NCI)  
National Institutes of Health (NIH)  
Bethesda, Maryland

# Disclosure Information


Sharmistha Ghosh-Janjigian

I have no financial relationships to disclose.

# The NCI Human Tumor Atlas Network (HTAN)\*

**Overarching program goal:** Construct dynamic 2D and 3D atlases of human cancers

- **Integrate** molecular, cellular, and tumor tissue composition and architecture, including the microenvironment and immune milieu
- Describe **transitions during cancer**: pre-malignant lesions to malignancy, locally invasive to metastatic cancer
- Enable **predictive modeling** to refine detection and therapeutic choices




\*HTAN Phase 1: 2018–2024

\*HTAN Phase 2: Launched in Fall 2024

HTAN Marker Paper, Cell 2020:  
<https://doi.org/10.1016/j.cell.2020.03.053>

# Tumor Atlases: Facilitating an Era of Precision Medicine






HTAN Marker Paper, Cell 2020:  
<https://doi.org/10.1016/j.cell.2020.03.053>

# HTAN Principles

- **Community Resource** – create a community resource that catalyzes cancer research across disciplines
- **Complementary Approaches** – strengths and weaknesses will be discovered as a Network; expect to work together
- **Open Communication** – accelerate science by breaking down walls; strive towards interoperability
- **Data and Resource Sharing** – requirement for success; expect aggressive public data/resource release timelines

# Multimodal and Spatial Atlases



Steering Committee

## HTAN Components:

- 5 Precancer Atlas Research Centers (PCA)
- 5 Human Tumor Atlas Research Centers (HTA)
- Data Coordinating Center (DCC)



# HTAN Phase 1 Tumor Types (2018–2024)

## LUNG

Avrum Spira and Steven Dubinett  
Boston University and University of California Los Angeles

Dana Pe'er and Christine Icabuzio-Donahue  
Memorial Sloan Kettering Cancer Center

Molecular and Cellular Characterization  
of Screen Detected Lesions (MCL)  
Consortium Pre-Cancer Atlas Pilot

## PANCREAS

Dana Pe'er and Christine Icabuzio-Donahue  
Memorial Sloan Kettering Cancer Center

MCL Consortium Pre-Cancer Atlas Pilot

Li Ding, Ryan Fields, William Gillanders  
and Samuel Achilefu  
Washington University in St. Louis

## COLON

Michael Snyder and James Ford  
Stanford University

Robert Coffey, Ken Lau and Martha Shrubsole  
Vanderbilt University

Bruce Johnson and Aviv Regev  
Dana-Farber Cancer Institute and Broad Institute

FNLCR and Broad Institute  
Tumor Atlas Pilot

## BREAST

Shelley Hwang, Carlo Maley and Robert West  
Duke University, Arizona State University and Stanford University

Joe Gray, Gordon Mills, Jeremy Goecks and George Thomas  
Oregon Health and Science University

Bruce Johnson and Aviv Regev  
Dana-Farber Cancer Institute and Broad Institute

Li Ding, Ryan Fields, William Gillanders and Samuel Achilefu  
Washington University in St. Louis

Frederick National Laboratory for Cancer Research (FNLCR)  
and Broad Institute Tumor Atlas Pilot

MCL Consortium Pre-Cancer Atlas Pilot

## SKIN


Peter Sorger, Sandro Santagata and Jon Aster  
Harvard University and Brigham and Women's Hospital

Bruce Johnson and Aviv Regev  
Dana-Farber Cancer Institute and Broad Institute

## PEDIATRIC

FNLCR and Broad Institute  
Tumor Atlas Pilot  
[glioma](#) / [neuroblastoma](#) / [sarcoma](#)

Kai Tan and Stephen Hunger  
Children's Hospital of Philadelphia  
[glioma](#) / [neuroblastoma](#) /  
[very high risk acute lymphoblastic leukemia](#)



# HTAN Phase 2 Tumor Types (Launched in Fall 2024)

## SKIN

**Melanoma and Cutaneous Squamous Cell Carcinoma**

**Alan Shain, Boris Bastian and Iwei Yeh**  
University of California, San Francisco

## PANCREAS

**Rosalie Sears, Elana Fertig, Jonathan Brody and Laura Wood**  
Oregon Health & Science University

## BRAIN

**Long Cai, Richard Everson, Matthew Thomson and Barbara Wold**  
California Institute of Technology

## GASTRIC

**Linghua Wang, Tae Hyun Hwang, Mingyao Li and Paul Mansfield**  
MD Anderson

## MYELOMA

**Irene Ghobrial**  
Dana Farber Cancer Institute

## PROSTATE

**Li Ding, Feng Chen, Eric Kim and Russell Pachynski**  
Washington University in St. Louis

## COLON

**Ken Lau and Jeffery Spraggins**  
Vanderbilt University

## OVARY


**Samuel Mok, Michael Birrer and Sammy Ferri-Borgogno**  
MD Anderson

## LYMPHOMA

**Rong Fan, Stephanie Halene, Zongming Ma and Mina Xu**  
Yale University

## PEDIATRIC SOLID TUMORS


**Rhabdomyosarcoma, Neuroblastoma and Wilms Tumor**  
**Shahab Asgharzadeh, James Amatruda and Long Cai**  
University of California, Los Angeles





# Interconnectivity Within HTAN

## HTAN Phase 1 Collaborative Projects



# Interconnectivity Across Community

## HTAN



HUMAN  
CELL  
ATLAS


2024 HTAN-HuBMAP  
Joint Meeting

2021/2022/2023  
Junior Atlas Builders  
Meetings

2020 NIH-HCA Joint  
Cell Atlas Meeting

Joint Data/Metadata  
Standards WG

Joint Image Analysis  
WG, Diversity &  
Inclusion WG



Cancer Immunoprevention Network (CIP-Net)

PREVENT Cancer Preclinical Drug Development  
Program


Cancer Prevention-Interception Targeted Agent  
Discovery Program (CAP-IT)

Translational and Basic Science Research in Early  
Lesions (TBEL) Program



# HTAN Data Jamborees


- Virtual HTAN Jamboree, Dec 2023, and In-Person HTAN Jamboree, Nov 2024
  - ~200 total participant applications
  - ~30 total project pitch submissions
- 87 participants were selected to work on 12 projects, each addressing a specific scientific question or technical challenge using available HTAN data
  - Promote access and reuse of HTAN data
  - Promote collaborations to expand the HTAN community
  - Promote development of new methods and tools for HTAN data analysis
  - Identify gaps and limitations of existing HTAN data and resources



November 2024 Data Jamboree Participants

# HTAN Associate Membership

- Associate Members are expected to contribute to HTAN by:
  - generating, sharing or analyzing data;
  - jointly developing software or algorithms;
  - developing mutually beneficial resources, protocols or reagents;
  - and/or coordinating development of standards, formats or metadata.
- Applications for Associate Membership require:
  - a letter of support from a current HTAN member;
  - a recent biosketch;
  - a letter of intent from the applicant describing their planned contributions to HTAN.
- Associate Members are encouraged to actively engage in HTAN activities
- Associate Member must abide by all HTAN policies





# HTAN *Nature* Bundle




## Watch accompanying webcast that explored:



Li Ding, PhD, WashU




Shannon Hughes, PhD  
NCI



Ken S. Lau, PhD  
Vanderbilt



Michael Snyder, PhD  
Stanford



Alexia-Ileana  
Zaromytidou, PhD  
(Moderator)

- The history of HTAN
- The goals of assembling cancer atlases
- Functioning of a successful multi-institution consortium
- In numbers: HTAN's scope and scale
- The power of spatial technologies
- Applying evolutionary principles in cancer research
- The importance of understanding the cancer microenvironment
- How you can use HTAN's resources for your own research
- The future of the field

*Thank You*